Investment
Features
FeesSafety
Academy
More
Pluang+

RH's creative chief Michael Brown leaves to lead Vesta Home's luxury furniture and design expansion

Market News
06 Oct 2026
Proactive Investors
View Source
Bearish
RH's creative chief Michael Brown leaves to lead Vesta Home's luxury furniture and design expansion

Michael Brown, senior vice president and global interior design leader at RH, has left the luxury home furnishings retailer to become chief creative officer at Vesta Home. At Vesta, he will oversee furniture collections and lead the expansion of its luxury interior design division. Brown's departure follows other key executive exits at RH and comes as the company invests in new business lines like RH Estates. Investment bank Jefferies maintains a 'hold' rating on RH, citing uncertainty over new business impact and margin pressures from international expansion. Meanwhile, Jefferies recommends a 'buy' on RH competitor Arhaus.

The story about RH's creative chief Michael Brown departing to join Vesta Home is presented here with a snapshot of the Consumer Cyclical sector on Pluang as of Oct 06, 2026 23:31 WIB. Of 112 priced US stocks in this sector, 74 rose and 38 fell. Among notable movers, AZO (Autozone Inc) rose 3.68% to USD 2,911.00 with a typical hold time of 71 days and 100% buy order activity, contrasting with ONON (ON Holding AG) which fell with 96% sell order activity despite a 3.45% price increase to USD 32.98.

More News

Bank OZK to report Q3 2026 earnings on Oct 20 amid Citigroup's Sell rating at $45.59

Bank OZK to report Q3 2026 earnings on Oct 20 amid Citigroup's Sell rating at $45.59

Bank OZK is scheduled to release its Q3 2026 earnings after market close on October 20, providing investors with updated financial results to compare against Citigroup's current Sell rating. The bank's latest balance sheet shows $41.70 billion in tot...

Company Fundamentals
Neutral
19 minutes ago
Scotiabank raises Pfizer price target to $33, signaling 20.9% potential gain.

Scotiabank raises Pfizer price target to $33, signaling 20.9% potential gain.

Scotiabank has increased its price target for Pfizer stock from $30.00 to $33.00, suggesting a potential upside of 20.9% from the current trading price of $27.31. Pfizer, a major pharmaceutical company, holds a strong buy rating with a Zacks Rank of ...

Analyst Insights
Bullish
1 hour ago
Citigroup raises AstraZeneca price target after strong clinical trial results

Citigroup raises AstraZeneca price target after strong clinical trial results

Citigroup has raised its price target for AstraZeneca to £186.00 from £178.00, maintaining a Buy rating following successful Phase 3 clinical trials. The increase reflects higher peak sales forecasts for drugs tozorakimab and SERENA-6, offsetting the...

Analyst Insights
Bullish
1 hour ago
Devon Energy shares seen rising 40% as analyst sets $67 price target amid asset sale pressures.

Devon Energy shares seen rising 40% as analyst sets $67 price target amid asset sale pressures.

An analyst from BMO Capital set a $67 price target for Devon Energy, suggesting a 40% upside from its current share price of around $48. The oil and gas producer has consistently beaten earnings estimates recently, showing strong financial health. Ho...

Analyst Insights
Bullish
2 hours ago
$10,000 in Marvell stock 10 years ago is now worth about $206,000, needing 35% annual growth to repeat.

$10,000 in Marvell stock 10 years ago is now worth about $206,000, needing 35% annual growth to repeat.

An investment of $10,000 in Marvell stock a decade ago has grown to approximately $206,000 today. Achieving the same growth again would require an annual earnings increase of 35%. This highlights Marvell's strong past performance and the challenge of...

Market News
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App